Cardiometabolism

Our Scientific Focus

Our working group focuses on metabolic changes in cardiovascular diseases. The interaction between cardiovascular diseases and conditions such as diabetes and chronic kidney disease, as well as inflammatory processes, is extremely important. Our goal is to develop a molecular understanding of the underlying disease processes at a cellular level, with a particular focus on the connections between cell growth, substrate utilization and mitochondrial function. This will help us to better understand existing therapies and identify new therapeutic targets. In particular, we are interested in the effects of incretin hormones (like GLP-1 and GIP), and SGLT2 inhibition on the cardiovascular system.

Group leader
Porträtfoto einer Frau mit blondem Haar, die ein helles Oberteil trägt und freundlich in die Kamera lächelt.

Dr. rer. medic. Julia Möllmann
Tel.: 0241 80-37089
jmoellmannukaachende

Teammitglieder

Minha Naveed
Technische Assistentin

Tabea Pirker
Technische Assistentin

Elisabeth Kunth, M. Sc.
Phd Studentin

 

 

Selected publications:

  • Development of a Mouse Model of Uremic Cardiomyopathy: Investigating the Impact of Chronic Kidney Disease on Cardiac Function and Signaling Pathway. Moellmann J, Glandien K, Klinkhammer BM, Wollenhaupt J, Noels H, Jankowski J, Lebherz C, Boor P, Lehrke M, Marx N. FASEB J. 2025 May 31;39(10):e70639. doi: 10.1096/fj.202500281R. PMID: 40386987.
  • 2,8-Dihydroxyadenine-induced nephropathy causes hexosylceramide accumulation with increased mTOR signaling, reduced levels of protective SirT3 expression and impaired renal mitochondrial function.; Moellmann J, Krueger K, Wong DWL, Klinkhammer BM, Buhl EM, Dehairs J, Swinnen JV, Noels H, Jankowski J, Lebherz C, Boor P, Marx N, Lehrke M.Biochim Biophys Acta Mol Basis Dis. 2024 Jan;1870(1):166825. doi: 10.1016/j.bbadis.2023.166825. Epub 2023 Aug 1.PMID: 37536502
  • The sodium-glucose co-transporter-2 inhibitor ertugliflozin modifies the signature of cardiac substrate metabolism and reduces cardiac mTOR signalling, endoplasmic reticulum stress and apoptosis.; Moellmann J, Mann PA, Kappel BA, Kahles F, Klinkhammer BM, Boor P, Kramann R, Ghesquiere B, Lebherz C, Marx N, Lehrke M.Diabetes Obes Metab. 2022 Nov;24(11):2263-2272. doi: 10.1111/dom.14814. Epub 2022 Aug 1.PMID: 35801343
  • Empagliflozin improves left ventricular diastolic function of db/db mice.; Moellmann J, Klinkhammer BM, Droste P, Kappel B, Haj-Yehia E, Maxeiner S, Artati A, Adamski J, Boor P, Schütt K, Lopaschuk GD, Verma S, Marx N, Lehrke M.Biochim Biophys Acta Mol Basis Dis. 2020 Aug 1;1866(8):165807. doi: 10.1016/j.bbadis.2020.165807. Epub 2020 Apr 28.PMID: 32353614
  • Glucagon-Like Peptide 1 and Its Cleavage Products Are Renoprotective in Murine Diabetic Nephropathy.; Moellmann J, Klinkhammer BM, Onstein J, Stöhr R, Jankowski V, Jankowski J, Lebherz C, Tacke F, Marx N, Boor P, Lehrke M.Diabetes. 2018 Nov;67(11):2410-2419. doi: 10.2337/db17-1212. Epub 2018 Aug 13.PMID: 30104246
  • The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism.; Möllmann J, Kahles F, Lebherz C, Kappel B, Baeck C, Tacke F, Werner C, Federici M, Marx N, Lehrke M.Diabetes Obes Metab. 2017 Apr;19(4):496-508. doi: 10.1111/dom.12839. Epub 2017 Feb 22.PMID: 27917591

 

For a complete reference list please see Link:

https://pubmed.ncbi.nlm.nih.gov/?term=Moellmann+j+aachen&sort=date
https://pubmed.ncbi.nlm.nih.gov/?term=M%C3%B6llmann+j+aachen&sort=date

 

  • Ernst und Berta Grimmke-Stiftung
  • START-Programm der RWTH Aachen